J Exp Clin Cancer Res 2009, 28: 69–81.CrossRefPubMed Competing interests The authors declare that they have no competing interests. Authors’ contributions MRG participated in the design and coordination of the study, LLA carried out most of the experiments, DEG and DFA conceived the study. All authors this website read and approved the final manuscript.”
“Background Cancer cells release protein markers into the peripheral blood, but these are difficult to detect in the

serum at the early stage of cancer. However, in the peripheral blood, circulating mononuclear cells may phagocytose cancer or precancer cells and, thereby, express epithelial markers within their phagocytosed contents. It is possible that tumor markers will show up in mononuclear cells before they themselves could be detected in the circulation. Therefore, mRNA expression of the genotype of these cells, in theory, can improve the sensitivity of detection of early cancers. The human telomerase reverse transcriptase (hTERT gene) mRNA expression is the most general molecular marker for the identification of human cancer and can be detected in 85% of all tumors, whereas most healthy tissues exhibit little or no expression [1–4].

In healthy esophagus tissue, hTERT expression is predominantly localized in the basal cell layers of the columnar epithelium [5]. Differential hTERT expression between tumor tissues and healthy tissues makes this gene a promising marker for the detection of tumor cells [6, 7]. Eyes {Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|buy Anti-diabetic Compound Library|Anti-diabetic Compound Library ic50|Anti-diabetic Compound Library price|Anti-diabetic Compound Library cost|Anti-diabetic Compound Library solubility dmso|Anti-diabetic Compound Library purchase|Anti-diabetic Compound Library manufacturer|Anti-diabetic Compound Library research buy|Anti-diabetic Compound Library order|Anti-diabetic Compound Library mouse|Anti-diabetic Compound Library chemical structure|Anti-diabetic Compound Library mw|Anti-diabetic Compound Library molecular weight|Anti-diabetic Compound Library datasheet|Anti-diabetic Compound Library supplier|Anti-diabetic Compound Library in vitro|Anti-diabetic Compound Library cell line|Anti-diabetic Compound Library concentration|Anti-diabetic Compound Library nmr|Anti-diabetic Compound Library in vivo|Anti-diabetic Compound Library clinical trial|Anti-diabetic Compound Library cell assay|Anti-diabetic Compound Library screening|Anti-diabetic Compound Library high throughput|buy Antidiabetic Compound Library|Antidiabetic Compound Library ic50|Antidiabetic Compound Library price|Antidiabetic Compound Library cost|Antidiabetic Compound Library solubility dmso|Antidiabetic Compound Library purchase|Antidiabetic Compound Library manufacturer|Antidiabetic Compound Library research buy|Antidiabetic Compound Library order|Antidiabetic Compound Library chemical structure|Antidiabetic Compound Library datasheet|Antidiabetic Compound Library supplier|Antidiabetic Compound Library in vitro|Antidiabetic Compound Library cell line|Antidiabetic Compound Library concentration|Antidiabetic Compound Library clinical trial|Antidiabetic Compound Library cell assay|Antidiabetic Compound Library screening|Antidiabetic Compound Library high throughput|Anti-diabetic Compound high throughput screening| absent 4 (EYA4) BIX 1294 chemical structure is one of four members of the EYA gene family that is homologous to the eyes absent gene in Drosophila [8–10].

Eyes absent works as a key regulator of ocular differentiation and may also modulate apoptosis. Recently, the value of methylated EYA4 as a marker for Barrette’s esophagus and esophageal adenocarcinoma many has been suggested [11, 12]. However, to our knowledge, no reports have yet linked expression of the EYA4 gene linkage with esophageal squamous cell carcinoma (ESCC). Endoscopic screening with Lugol dye and pathologic evaluation are useful screening tools for early stage esophageal cancer and for ascertaining the different stages of esophageal carcinogenesis in populated areas with high incidence [13]. However, the lack of strict scientific methods for determining high-risk persons who should undergo endoscopic testing, and the resulting cost-efficiency issues, currently impede this type of screening. Even in areas with high incidence of ESCC, the detection rate of ESCC in situ or at early stage is very low. A crucial requirement is a reliable method for distinguishing healthy persons and high-risk persons in need of an endoscopic test.